Skip to main content

Table 2 Inflammatory biomarkers and hepatic characteristic changes after 12 week of intervention

From: Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

characteristic

Baseline

After 12 week

P a

Change (%)

P b

hs-CRP (ng/dL)

 Curcumin group

5647.1 ± 3858.4

4653.8 ± 4243.8

0.12

− 993.3 ± 385.4

0.660

 Placebo group

6705.0 ± 4794.9

5310.2 ± 5071.7

0.53

− 1394.8 ± 276.8

TNF-α (pg/mL)

 Curcumin group

19.34 ± 5.4

16.51 ± 4.5

< 0.001

−2.83 ± 0.9

0.972

 Placebo group

18.63 ± 2.2

16.54 ± 2.1

0.02

−2.09 ± 0.1

NF-κB

 Curcumin group

2.07 ± 1.03

1.65 ± 0.63

0.044

−0.49 ± 0.29

0.539

 Placebo group

2.13 ± 0.92

2.03 ± 0.51

0.209

− 0.26 ± 0.20

ALT (IU/L)

 Curcumin group

26.54 ± 15.46

20.82 ± 10.09

< 0.001

−5.58 ± 14.6

0.778

 Placebo group

28.02 ± 13.06

21.2 ± 7.72

< 0.001

−6.82 ± 15.8

AST (IU/L)

 Curcumin group

17.78 ± 9.56

14.75 ± 7.45

< 0.001

−2.76 ± 7.54

0.728

 Placebo group

16.23 ± 5.66

12.77 ± 4.05

< 0.001

−3.46 ± 5.43

 

Fibrosis (kPa)

 Curcumin group

6.98 ± 2.42

6.2 ± 2.38

< 0.001

−0.78 ± 0.89

0.364

 Placebo group

6.52 ± 2.38

6.02 ± 1.8

0.095

−0.49 ± 1.15

Steatosis (db/m)

 Curcumin group

298.35 ± 29.5

282.65 ± 40.09

0.015

−15.69 ± 30.72

0.112

 Placebo group

315.18 ± 35.69

283.18 ± 49.83

0.001

−32 ± 34.3

  1. NAFLD none-alcoholic Fatty Liver Disease, BMI: body mass index, TNF tumor necrosis factor, NF-kB Nuclear factor kappa B, hs-CRP high sensitive C reactive protein, ALT Alanine aminotransferase, AST Aspartate aminotransferase
  2. aP values indicate comparison within groups
  3. bP values indicate comparison between the changes of each variable between 2 groups